{"id":"rivaroxaban-oral-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban selectively inhibits Factor Xa, a key enzyme in the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa, it prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and inhibiting clot formation. This anticoagulant effect is used to prevent and treat thrombotic events.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:27.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis (DVT) treatment and prevention"},{"name":"Pulmonary embolism (PE) treatment and prevention"},{"name":"Acute coronary syndrome"},{"name":"Thromboprophylaxis after hip or knee replacement surgery"}]},"trialDetails":[{"nctId":"NCT05009862","phase":"PHASE4","title":"The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-19","conditions":"Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT04874428","phase":"PHASE1","title":"Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-05-19","conditions":"Liver Cirrhosis","enrollment":24},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT06396858","phase":"PHASE4","title":"Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2026-07","conditions":"Ischemic Stroke","enrollment":4500},{"nctId":"NCT04258488","phase":"PHASE4","title":"Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement","status":"RECRUITING","sponsor":"Joon Bum Kim","startDate":"2022-02-21","conditions":"AORTIC VALVE DISEASES, Thromboembolism","enrollment":1300},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT04755283","phase":"PHASE2","title":"Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2021-02-02","conditions":"Atrial Fibrillation (AF), Stroke","enrollment":1287},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT06220123","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","status":"COMPLETED","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2024-02-16","conditions":"Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","enrollment":225},{"nctId":"NCT06580223","phase":"PHASE3","title":"Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-09-01","conditions":"Multiple Myeloma, Venous Thromboembolism","enrollment":530},{"nctId":"NCT06831474","phase":"PHASE1","title":"Excretion of Rivaroxaban in Human Breast Milk","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-07","conditions":"Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism)","enrollment":10},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT06986369","phase":"PHASE4","title":"Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2021-05-04","conditions":"Atherosclerosis, Coronary","enrollment":140},{"nctId":"NCT03129490","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":11000},{"nctId":"NCT03630055","phase":"PHASE3","title":"Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-10-03","conditions":"Radial Artery Occlusion","enrollment":1800},{"nctId":"NCT03129555","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5000},{"nctId":"NCT06862726","phase":"PHASE4","title":"Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation","status":"ENROLLING_BY_INVITATION","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2024-12-01","conditions":"Non Valvular Atrial Fibrillation","enrollment":120},{"nctId":"NCT06611319","phase":"PHASE3","title":"ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty","status":"RECRUITING","sponsor":"Prof. Stavros Konstantinides, MD","startDate":"2024-11-26","conditions":"Hip Arthroplasty, Total, Prevention of Venous Thromboembolism","enrollment":2932},{"nctId":"NCT05775965","phase":"PHASE2","title":"HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot)","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2024-05-21","conditions":"Hip Fractures","enrollment":250},{"nctId":"NCT03996772","phase":"PHASE3","title":"PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-06-03","conditions":"Atrial Fibrillation, Intracerebral Hemorrhage","enrollment":319},{"nctId":"NCT06372483","phase":"PHASE1","title":"Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-02-21","conditions":"Coagulation Disorder","enrollment":40},{"nctId":"NCT03522259","phase":"PHASE2","title":"Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-07-19","conditions":"Bariatric Surgery","enrollment":272},{"nctId":"NCT06531122","phase":"PHASE3","title":"Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2021-08-01","conditions":"Cerebral Venous Thrombosis","enrollment":200},{"nctId":"NCT06558045","phase":"PHASE1","title":"Bioequivalence Study of Rivaroxaban 20 mg Film-coated Tablets","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2023-07-06","conditions":"Healthy","enrollment":26},{"nctId":"NCT06558058","phase":"PHASE1","title":"Bioequivalence Study of Rivaroxaban 10 mg Film-coated Tablets","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2023-06-08","conditions":"Healthy","enrollment":28},{"nctId":"NCT06551402","phase":"PHASE3","title":"Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-09","conditions":"Cerebral Venous Sinus Thrombosis","enrollment":200},{"nctId":"NCT04853719","phase":"PHASE4","title":"Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients","status":"COMPLETED","sponsor":"Science Valley Research Institute","startDate":"2021-04-20","conditions":"Peripheral Artery Disease, Intermittent Claudication","enrollment":88},{"nctId":"NCT04128956","phase":"PHASE2","title":"Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2020-03-11","conditions":"Venous Thromboses, Stent Stenosis","enrollment":172},{"nctId":"NCT04324463","phase":"PHASE3","title":"Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2020-04-21","conditions":"Coronavirus, Severe Acute Respiratory Syndrome","enrollment":6667},{"nctId":"NCT05723510","phase":"PHASE1","title":"PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2023-03-06","conditions":"Healthy","enrollment":87},{"nctId":"NCT03684564","phase":"PHASE2","title":"RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-07-09","conditions":"Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke","enrollment":43},{"nctId":"NCT03864406","phase":"PHASE1","title":"Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2019-06-04","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT06145269","phase":"EARLY_PHASE1","title":"Recanalization Rate of Acute DVT","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-12-01","conditions":"Acute DVT of Lower Extremity","enrollment":100},{"nctId":"NCT04273516","phase":"PHASE2, PHASE3","title":"Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2020-08-22","conditions":"Stroke, Prevention","enrollment":42},{"nctId":"NCT04142125","phase":"PHASE3","title":"Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2020-02-03","conditions":"Ischemic Stroke, Intracranial Atherosclerotic Disease","enrollment":101},{"nctId":"NCT05973188","phase":"PHASE4","title":"Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial","status":"UNKNOWN","sponsor":"Peshawar Institute of Cardiology","startDate":"2023-05-01","conditions":"Left Ventricular Thrombus","enrollment":141},{"nctId":"NCT04508023","phase":"PHASE3","title":"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-08-13","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":1284},{"nctId":"NCT04838808","phase":"PHASE2, PHASE3","title":"Rivaroxaban in Type 2 Myocardial Infarctions","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-04-05","conditions":"Type II Myocardial Infarction","enrollment":8},{"nctId":"NCT05718531","phase":"PHASE3","title":"Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-02-01","conditions":"Coronary Artery Ectasia","enrollment":200},{"nctId":"NCT04757857","phase":"PHASE4","title":"COVID-19 Antithrombotic Rivaroxaban Evaluation","status":"TERMINATED","sponsor":"Hospital Alemão Oswaldo Cruz","startDate":"2020-09-29","conditions":"COVID-19","enrollment":660},{"nctId":"NCT05546320","phase":"PHASE4","title":"Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-10-15","conditions":"Patent Foramen Ovale, Migraine","enrollment":1000},{"nctId":"NCT01776424","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-28","conditions":"Prevention & Control","enrollment":27395},{"nctId":"NCT02664155","phase":"PHASE3","title":"Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2016-10-19","conditions":"Renal Insufficiency","enrollment":203},{"nctId":"NCT05573958","phase":"PHASE4","title":"To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Sarmad Zahoor","startDate":"2022-10-01","conditions":"Acute Coronary Syndrome","enrollment":90},{"nctId":"NCT04689919","phase":"PHASE1","title":"Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions","status":"COMPLETED","sponsor":"University of Karachi","startDate":"2022-02-19","conditions":"Bioequivalence","enrollment":26},{"nctId":"NCT05515120","phase":"PHASE2, PHASE3","title":"Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2021-01-03","conditions":"Venous Thromboembolism, Anticoagulant-induced Bleeding, Venous Thromboses","enrollment":58},{"nctId":"NCT05418803","phase":"PHASE1","title":"BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2020-01-28","conditions":"Healthy Volunteer","enrollment":34},{"nctId":"NCT03181386","phase":"PHASE3","title":"Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-05-03","conditions":"Atrial Fibrillation, Periodontal Disease, Hemorrhage","enrollment":60},{"nctId":"NCT04994223","phase":"EARLY_PHASE1","title":"Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease","status":"UNKNOWN","sponsor":"Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi","startDate":"2021-07-02","conditions":"Combined Anticoagulation and Antithrombotic Therapy, PAD - Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT05210725","phase":"PHASE4","title":"Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-03-01","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT05300555","phase":"PHASE4","title":"Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-01-05","conditions":"Atrial Fibrillation New Onset","enrollment":50},{"nctId":"NCT03055026","phase":"PHASE3","title":"Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.","status":"COMPLETED","sponsor":"Fadoi Foundation, Italy","startDate":"2017-05-03","conditions":"Prevention of Venous Thromboembolism","enrollment":582},{"nctId":"NCT05088928","phase":"PHASE2","title":"Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care","status":"UNKNOWN","sponsor":"Scotmann Pharmaceuticals","startDate":"2022-03-01","conditions":"COVID-19","enrollment":40},{"nctId":"NCT05128591","phase":"PHASE1","title":"A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2021-11-09","conditions":"Embolism and Thrombosis","enrollment":38},{"nctId":"NCT05233124","phase":"PHASE2","title":"Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2021-09-01","conditions":"Acute Coronary Syndrome, Coronary Artery Ectasia","enrollment":60},{"nctId":"NCT04218656","phase":"PHASE4","title":"DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-06-08","conditions":"Peripheral Artery Disease","enrollment":159},{"nctId":"NCT04504032","phase":"PHASE2","title":"A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2020-09-02","conditions":"COVID-19","enrollment":497},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT03926156","phase":"PHASE3","title":"RIvoraxaban in Mitral Stenosis","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2019-05-22","conditions":"Mitral Stenosis, Rheumatic Heart Disease, Atrial Fibrillation","enrollment":40},{"nctId":"NCT04673214","phase":"PHASE3","title":"Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment","status":"COMPLETED","sponsor":"Gilberto Cruz Arteaga","startDate":"2020-12-16","conditions":"Covid19","enrollment":114},{"nctId":"NCT04942873","phase":"","title":"The Adherence to Oral Anticoagulant in Chinese Patients With NVAF","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-07-20","conditions":"Nonvalvular Atrial Fibrillation","enrollment":500},{"nctId":"NCT04753489","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2021-02-13","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT04729998","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2021-01-30","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT04727021","phase":"PHASE1","title":"A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-07-04","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT04720092","phase":"PHASE1","title":"A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-07-05","conditions":"Thromboembolic Disorders","enrollment":30},{"nctId":"NCT04715295","phase":"PHASE4","title":"Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19","status":"UNKNOWN","sponsor":"Yaounde Central Hospital","startDate":"2020-10-05","conditions":"COVID-19","enrollment":200},{"nctId":"NCT02504216","phase":"PHASE3","title":"Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-18","conditions":"Peripheral Artery Disease","enrollment":6564},{"nctId":"NCT03799822","phase":"PHASE4","title":"Oral Anticoagulation in Hemodialysis","status":"COMPLETED","sponsor":"Onze Lieve Vrouw Hospital","startDate":"2017-05-01","conditions":"Atrial Fibrillation","enrollment":132},{"nctId":"NCT02066662","phase":"PHASE4","title":"Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2013-07","conditions":"Atrial Fibrillation or Pulmonary Embolism, Need of Long Term Oral Anticoagulation Therapy (OAT), Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location","enrollment":192},{"nctId":"NCT04059679","phase":"PHASE4","title":"Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy","status":"UNKNOWN","sponsor":"LifeBridge Health","startDate":"2020-01-30","conditions":"Coronary Artery Disease, Peripheral Artery Disease","enrollment":30},{"nctId":"NCT04511611","phase":"PHASE1","title":"Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-01-24","conditions":"Clinical Pharmacology","enrollment":80},{"nctId":"NCT04511637","phase":"PHASE1","title":"Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-01-21","conditions":"Clinical Pharmacology","enrollment":80},{"nctId":"NCT04424381","phase":"PHASE1","title":"Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2019-06-04","conditions":"Healthy Subjects","enrollment":72},{"nctId":"NCT03119116","phase":"","title":"Use of Direct Oral Anticoagulants in UK","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-05-15","conditions":"Stroke","enrollment":31336},{"nctId":"NCT02234843","phase":"PHASE3","title":"EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-11-13","conditions":"Venous Thromboembolism","enrollment":500},{"nctId":"NCT04169269","phase":"PHASE4","title":"Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban","status":"UNKNOWN","sponsor":"Florida Orthopaedic Institute","startDate":"2020-01-13","conditions":"Deep Vein Thrombosis, Venous Thromboembolism","enrollment":128},{"nctId":"NCT02111564","phase":"PHASE3","title":"A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-07","conditions":"Heart Failure, Respiratory Insufficiency, Stroke Acute","enrollment":12024},{"nctId":"NCT02161965","phase":"PHASE4","title":"Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2013-05-21","conditions":"Permanent Atrial Fibrillation, Venous Thrombosis, Pulmonary Embolism","enrollment":51},{"nctId":"NCT02555878","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-11","conditions":"Neoplasms","enrollment":841},{"nctId":"NCT04023630","phase":"PHASE4","title":"DUAL Antithrombotic Therapy in Patients With AF and ACS","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2019-10-01","conditions":"Atrial Fibrillation, Acute Coronary Syndromes","enrollment":4000},{"nctId":"NCT01877915","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-10","conditions":"Heart Failure, Coronary Artery Disease","enrollment":5081},{"nctId":"NCT02610933","phase":"PHASE4","title":"Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients","status":"COMPLETED","sponsor":"Onze Lieve Vrouw Hospital","startDate":"2015-11","conditions":"Vascular Calcification","enrollment":117},{"nctId":"NCT02970773","phase":"PHASE4","title":"Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury","status":"WITHDRAWN","sponsor":"Swiss Paraplegic Research, Nottwil","startDate":"2017-12-04","conditions":"Spinal Cord Injuries, Thromboembolism","enrollment":""},{"nctId":"NCT02313909","phase":"PHASE3","title":"Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)","status":"TERMINATED","sponsor":"Bayer","startDate":"2014-12-23","conditions":"Stroke","enrollment":7213},{"nctId":"NCT02157272","phase":"PHASE3","title":"Rivaroxaban in Thrombotic Antiphospholipid Syndrome","status":"TERMINATED","sponsor":"University of Padova","startDate":"2014-12","conditions":"Antiphospholipid Syndrome","enrollment":121},{"nctId":"NCT02293395","phase":"PHASE2","title":"A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-04-20","conditions":"Acute Coronary Syndrome","enrollment":3037},{"nctId":"NCT01684423","phase":"PHASE2","title":"Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-19","conditions":"Venous Thrombosis","enrollment":64},{"nctId":"NCT01830543","phase":"PHASE3","title":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-05-10","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2124},{"nctId":"NCT02289703","phase":"PHASE1","title":"A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-01","conditions":"End-Stage Renal Disease","enrollment":16},{"nctId":"NCT01400646","phase":"PHASE1","title":"A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-10","conditions":"Healthy","enrollment":46},{"nctId":"NCT01464450","phase":"PHASE1","title":"Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2011-10","conditions":"Pharmacokinetics, Bioavailability, Healthy Participants","enrollment":55},{"nctId":"NCT01656330","phase":"PHASE1","title":"A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-07","conditions":"Healthy","enrollment":35},{"nctId":"NCT01853800","phase":"PHASE1","title":"Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-05","conditions":"Biological Availability","enrollment":14},{"nctId":"NCT00571649","phase":"PHASE3","title":"Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Venous Thromboembolism","enrollment":8101},{"nctId":"NCT02271399","phase":"PHASE2","title":"Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Hanyang University Seoul Hospital","startDate":"2014-10","conditions":"Venous Thromboembolism","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rivaroxaban Oral Tablet","genericName":"Rivaroxaban Oral Tablet","companyName":"Swiss Paraplegic Research, Nottwil","companyId":"swiss-paraplegic-research-nottwil","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}